Orexo
Develops pharmaceuticals and digital therapies for substance use and mental health.
ORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000736415 (+2 more)
- LEI:
- 549300LJ5CCWDPTK9Z08
- Country:
- Sweden
- Address:
- Box 303, 751 05 UPPSALA
- Website:
- https://orexo.com/
- Sector:
- Manufacturing
Description
Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2015-03-25 09:30 | Swedish | 2.3 MB | |||
| 2015-03-25 09:30 | English | 2.8 MB | |||
| 2015-03-16 11:01 |
Notice of Annual General Meeting of Orexo
|
English | 490.2 KB | ||
| 2015-03-16 11:01 |
Kallelse till årsstämma i Orexo
|
Swedish | 378.4 KB | ||
| 2015-02-17 08:30 |
Orexo breddar produktsortimentet för Zubsolv® och meddelar listning av ett nytt…
|
Swedish | 339.1 KB | ||
| 2015-02-17 08:30 |
Orexo broadens ZUBSOLV® product range and announces newly listed granted US pat…
|
English | 347.1 KB | ||
| 2015-02-05 08:00 |
Orexo stämmer Actavis för patentintrång avseende Abstral® i USA
|
Swedish | 340.2 KB | ||
| 2015-02-05 08:00 |
Orexo commences patent infringement litigation against Actavis concerning Abstr…
|
English | 345.5 KB | ||
| 2015-01-30 17:30 |
Antal aktier och röster i Orexo
|
Swedish | 326.2 KB | ||
| 2015-01-30 17:30 |
Number of shares and votes in Orexo
|
English | 333.2 KB | ||
| 2015-01-29 13:37 | English | 34.1 KB | |||
| 2015-01-29 08:00 | Swedish | 1.4 MB | |||
| 2015-01-29 08:00 | English | 1.5 MB | |||
| 2015-01-15 08:30 |
Orexo Receives Paragraph IV Notice Letter Concerning Abstral® in the US
|
English | 288.4 KB | ||
| 2015-01-15 08:30 |
Orexo har mottagit Paragraph IV-meddelande rörande Abstral® i USA
|
Swedish | 280.6 KB |
Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Orexo
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Orexo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-11 | Nikolaj Arrild Sørensen | Other | Buy | 2,460 | 35,178.00 SEK |
| 2025-04-04 | Nikolaj Arrild Sørensen | Other | Buy | 3,500 | 47,530.00 SEK |
| 2024-03-26 | Fredrik Järrsten | Other | Buy | 3,000 | 44,040.00 SEK |
| 2023-11-24 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 44,640.00 SEK |
| 2023-11-08 | Fredrik Järrsten | Other | Buy | 1,500 | 23,715.00 SEK |
| 2023-02-24 | Nikolaj Arrild Sørensen | Other | Buy | 11,500 | 188,945.00 SEK |
| 2023-01-27 | Fredrik Järrsten | Other | Buy | 4,500 | 79,695.00 SEK |
| 2022-07-26 | Michael Matly | Other | Buy | 2,820 | 60,777.77 SEK |
| 2022-07-21 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 61,500.00 SEK |
| 2022-07-15 | James Noble | Other | Buy | 18,500 | 394,252.80 SEK |
Peer Companies
